Form 4: AnaptysBio Chief Medical Officer Acquires 50,000 Performance Stock Units

Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc., acquired 50,000 performance stock units (PSUs) on July 22, 2024, contingent upon the achievement of certain share price metrics.

Summary

• On July 22, 2024, Paul F. Lizzul, the Chief Medical Officer of AnaptysBio, Inc., acquired 50,000 performance stock units (PSUs).
• Each PSU represents a contingent right to receive one share of AnaptysBio's common stock upon settlement for no consideration.
• The PSUs vest upon the achievement of certain share price metrics.
• 50% of the shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.
• An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects alignment of management interests with shareholders through performance-based compensation. The vesting conditions tied to share price performance suggest confidence in the company's future prospects.

Positives

• The acquisition of performance stock units by a key executive aligns their interests with the company's performance and shareholder value.
• The vesting schedule incentivizes long-term performance and continued service of the Chief Medical Officer.

Risks

• The value of the PSUs is contingent upon AnaptysBio achieving specific share price metrics, which may not be realized.
• The vesting is subject to the Reporting Person's continued service, creating a potential risk if the executive leaves the company before the vesting dates.

Future Outlook

The vesting of the PSUs is tied to the achievement of certain share price metrics, indicating a focus on increasing shareholder value.

Industry Context

The granting of performance-based equity compensation is a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This aligns with industry standards for incentivizing key personnel.

Comparison to Industry Standards

• Many biotech companies, such as Amgen, Regeneron, and Biogen, utilize performance-based equity compensation to align executive incentives with shareholder value creation.
• These companies often tie vesting to specific clinical trial milestones, regulatory approvals, or revenue targets, similar to AnaptysBio's share price metrics.
• The vesting schedules, typically spanning several years, are also consistent with industry practices to encourage long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the performance metrics are achieved, leading to vesting of the PSUs.
• Employees: Positive signal of confidence in the company's future prospects.
• Management: Incentivized to drive company performance and increase share price.

Key Dates